Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells.

Détails

ID Serval
serval:BIB_92772F6F7522
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells.
Périodique
Journal of Urology
Auteur⸱e⸱s
Wen B., Deutsch E., Eschwege P., De Crevoisier R., Nasr E., Eschwege F., Bourhis J.
ISSN
0022-5347 (Print)
ISSN-L
0022-5347
Statut éditorial
Publié
Date de publication
2003
Peer-reviewed
Oui
Volume
170
Numéro
5
Pages
2036-2039
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish
Résumé
PURPOSE: We examined the potential therapeutic effect of NS398, a selective cyclooxygenase-2 (COX-2) inhibitor, combined with irradiation on human prostate adenocarcinoma DU145 cells.
MATERIALS AND METHODS: The effect on tumor growth, proliferation testing and clonogenic survival was determined to evaluate its antitumor effect when exposed to NS398 or combined with irradiation. Immunoblotting analyses were done to detect the expression of COX-2, nuclear factor-kappaB p50 and Rel A p65 because evidence suggested a biological association of COX-2 with alterations in these markers. Reverse transcriptase-polymerase chain reaction was also performed to show its effect on the transcription level of COX-2.
RESULTS: Exposure of DU145 cells to NS398 alone suppressed proliferation in a dose and time dependent manner. Examination of the NS398 effect on the radiation response showed marked enhancement of radiosensitivity. Western blot indicated that NS398 down-regulated the expression of COX-2, nuclear factor-kappaB, p50 and Rel A p65, whereas the effect was more pronounced when combined with irradiation. Reverse transcriptase-polymerase chain reaction showed that the NS398 antitumor effect was associated with COX-2 transcription inhibition. Importantly COX-2 expression was enhanced by irradiation but this phenomenon was abolished when cells were exposed to NS398. Inhibition of tumor growth in animal model was observed when mice were treated with NS398 alone and irradiation alone, and this effect was maximal when treated with NS398 and irradiation.
CONCLUSIONS: These results suggest that NS398 could be used as a potential therapeutic agent combined with irradiation for prostate adenocarcinoma.
Mots-clé
Adenocarcinoma/genetics, Adenocarcinoma/pathology, Cell Division/drug effects, Cell Division/genetics, Cell Survival/drug effects, Cell Survival/genetics, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Cyclooxygenase Inhibitors/pharmacology, Down-Regulation/drug effects, Down-Regulation/radiation effects, Gene Expression Regulation, Enzymologic/drug effects, Gene Expression Regulation, Enzymologic/radiation effects, Humans, Isoenzymes/antagonists & inhibitors, Isoenzymes/genetics, Male, Membrane Proteins, NF-kappa B/genetics, Nitrobenzenes/pharmacology, Prostaglandin-Endoperoxide Synthases/genetics, Prostatic Neoplasms/genetics, Prostatic Neoplasms/pathology, Radiation-Sensitizing Agents/pharmacology, Reverse Transcriptase Polymerase Chain Reaction, Sulfonamides/pharmacology, Tumor Cells, Cultured/drug effects, Tumor Cells, Cultured/pathology
Pubmed
Création de la notice
01/12/2014 17:57
Dernière modification de la notice
20/08/2019 14:55
Données d'usage